In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide), produced by Fortune 500 ...

Sold under brand names including Wegovy and Ozempic, semaglutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), hence the technical term for it is a GLP-1 receptor agonist.

Are you a print subscriber? Activate your account. By Tim Nudd - 14 min 58 sec ago 2 hours 35 min ago By Parker Herren - 2 hours 48 min ago By Brian Bonilla - 2 hours 48 min ago By Jean-Paul ...

Since its online debut late last month, the one-minute ad pitching the company’s legal knockoff of the weight-loss drug Wegovy has stoked the controversy over the high costs of a new generation ...

After telehealth brand Hims & Hers aired its first Super Bowl commercial Sunday night, competitor Novo Nordisk, which makes competing weight loss drugs Ozempic and Wegovy, responded with its own ...

An "exciting" new study has found that Semaglutide, the active ingredient of Wegovy and Ozempic, could help people to reduce their alcohol intake. The drugs were originally developed to treat type ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Ozempic and Wegovy come in special injector pens that make it easy to get the dosing right. But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens.

The first clinical trial of its kind found the weekly jab semaglutide, also known as Ozempic and Wegovy, cuts the amount people drink in one day by about 40% and dramatically reduced the desire ...

Here is more information on Wegovy, how to decide if it’s right for you, and what you need to know about the Wegovy ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...